β-lactams against emerging 'superbugs': Progress and pitfalls

Expert Review of Clinical Pharmacology

Volumn 1, Issue 4, 2008, Pages 559-571

  Helfand, Marion Skalweit ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lactamase inhibitor; Anti methicilin resistant staphylococcus aureus carbapenems; Ceftaroline; Ceftobiprole; Doripenem; Methicilin resistant staphylococcus aureus; Multidrug resistant acinetobacter; NXL 104; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CARBAPENEMASE; CEFALEXIN; CEFTAROLINE FOSAMIL; CEFTOBIPROLE MEDOCARIL; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CILASTATIN PLUS IMIPENEM; CP 5609; DORIBAX; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; LEVOFLOXACIN; LINEZOLID; ME 1036; MINOCYCLINE; OUTER MEMBRANE PROTEIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PORIN; PPI 0903M; PZ 601; SM 216601; SMP 216601; SMP 601; T 91825; TIGECYCLINE; TOMOPENEM; UNINDEXED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ENTEROBACTERIACEAE; GRAM POSITIVE BACTERIUM; HOSPITAL CARE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANCE; PENICILLIN RESISTANCE; PSEUDOMONAS AERUGINOSA; RECOMMENDED DRUG DOSE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 49449109243     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.4.559     Document Type: Review

References (113)

1. Kim SH, Kim KH, Kim HB et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 52(1), 192-197 (2008).
2. Stryjewski ME, Szczech LA, Benjamin DKJ et al. Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin. Infect. Dis. 44(2), 190-196 (2007).
3. Fuda C SM, Vakulenko SB, Mobashery S. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279(39), 40802-40806 (2004).
4. Martins A, Cunha ML. Methicillin resistance in Staphylococcus aureus and coagulase-negative staphylococci: epidemiological and molecular aspects. Microbiol. Immunol. 51(9), 787-795 (2007).
5. Lemaire S, Fuda C, Van Bambeke F, Tulkens PM, Mobashery S. Restoration of susceptibility of methicillin-resistant staphylococcus aureus (MRSA) to β-lactam antibiotics by acidic PH: role of penicillin-binding protein 2A (PBP 2A). J. Biol. Chem. 283(19), 12769-12776 (2008).
6. Lim D, Strynadka NC. Structural basis for the β lactam resistance of PBP2a from methicillin-resistant Staphylococcus aureus. Nat. Struct: Biol. 9(11), 870-876 (2002).
7. Roychoudhury S, Dotzlaf JE, Ghag S, Yeh WK. Purification, properties, and kinetics of enzymatic acylation with β-lactams of soluble penicillin-binding protein 2a. A major factor in methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 269(16), 12067-12073 (1994).
8. Graves-Woodward K, Pratt RF. Reaction of soluble penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus with β-lactams and acyclic substrates: kinetics in homogeneous solution. Biochem. J. 332(Pt 3), 755-761 (1998).
9. Berger-Bächi B, Rohrer S. Factors influencing methicillin resistance in staphylococci. Arch. Microbiol. 178(3), 165-171 (2002).
10. Davies TA, Page MG, Shang W, Andrew T, Kania M, Bush K. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51(7), 2621-2624 (2007).
11. Page MG. Anti-MRSA β-lactams in development. Curr. Opin. Pharmacol. 6(5), 480-485 (2006).
12. Centers for Disease Control and Prevention. Vancomycin resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. 51(40), 902 (2002).
13. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. Vancomycin-resistant Staphylecoccus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46(5), 668-674 (2008).
14. Tenover FC. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin. Infect. Dis. 46(5), 675-677 (2008).
15. Jacobs MR, Good CE, Beall B, Bajaksouzian S, Windau AR, Whitney CG. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 46(3), 982-990 (2008).
16. Rice LB. Antimicrobial resistance in Gram-positive bacteria. Am. J. Med. 119(6 Suppl. 1), S11-S19; discussion S62-S70 (2006).
17. Jones RN. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn. Microbiol. Infect. Dis. 31(3), 461-466 (1998).
18. Helfand MS, Bonomo RA. β-lactamases: a survey of protein diversity. Curr. Drug Targets Infect. Disord. 3(1), 9-23 (2003).
19. Crowder MW, Spencer J, Vila AJ. Metallo-β-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc. Chem. Res. 39(10), 721-728 (2006).
20. Ambler R.P. The structure of β-lactamases. Philos. Trans. R. Soc. Lond. B Biol. Sci. 289, 321-331 (1980).
21. Huovinen P, Huovinen S, Jacoby GA. Sequence of PSE-2 β-lactamase. Antimicrob. Agents Chemother. 32(1), 134-136 (1988).
22. Jaurin B, Grundström T. AmpC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type. Proc. Natl Acad. Sci. USA 78(8), 4897-4901 (1981).
23. Ouellette M, Bissonncrte L, Roy PH. Precise insertion of antibiotic resistance determinants into Tn21-like transposons: nucleotide sequence of the OXA-1 β-lactamase gene. Proc. Natl Acad. Sci. USA 84(21), 7378-7382 (1987).
24. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39(6), 1211-1233 (1995).
25. Jacoby GA, Munoz-Price LS. The new β-lactamases. N. Engl. J. Med. 352(4), 380-391 (2005).
26. Walsh TR, Toleman MA, Poirel L, Nordmann P, Metallo-β-lactamases: the quiet befbre the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
27. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin. Infect. Dis. 42(Suppl. 4), S164-S172 (2006).
28. Rodríguez-Baño J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin. Infect. Dis. 43(11), 1407-1414 (2006).
29. Helfand MS, Bonomo RA. Extended-spectrum β-lactainases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections. Clin. Infect. Dis. 43(11), 1415-1416 (2006).
30. Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob. Agents Chemother. 49(2), 776-778 (2005).
31. Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165(12), 1430-1435. (2005).
32. Bratu S, Moory M, Nichani S et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49(7), 3018-3020. (2005).
33. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56(1), 128-132 (2005).
34. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46(1), 1-11 (2002).
35. Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. J. Antimicrob. Chemother. 57(3), 373-383 (2006).
36. Golemi D, Maveyraud L, Vakulenko S et al. The first structural and mechanistic insights for class D β-lactamases: evidence for a novel catalytic process for turnover of β-lactam antibiotics. J. Am. Chem. Soc. 122, 6132 (2000).
37. Totir MA, Cha J, Ishiwata A et al. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 β-lactamase: Raman crystallographic eidence. Biochemistry 47(13), 4094-4101 (2008).
38. Anderson DL. Doripenem. Drugs Today (Barcelona) 42(6), 399-404 (2006).
39. Rea-Neto A, Niederman M, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficay and safety of intravenous doripenem vs piperacillin/tazobactam in nosocomial pneumonia. Presented at: 47th Intencience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
40. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of doripnem vs imipenem for ventilator associated pneumonia. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
41. Kaniga K, Redman R, Llorens L, Friedland I. Prevalence of extended spectrum β-lactamase producers (ESBLs) and fluoroquinolone-resistant isolates from phase 3 trials of complicated urinary tract infections (UTIs) including pyelonephritis. Presented at: 47th Intencience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
42. Chen Y, Garber E, Zhao Q et al. In vitro activity of doripenem (S-4661) against multidrug-resistant Gram-negative bacilli isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 49(6), 2510-2511 (2005).
43. Traczewski MM, Brown SD. In vitro activity of doripenem against Pseudomonas aeruginosa and Burkholderia cepacia isolates from both cystic fibrosis and non-cystic fibrosis patients. Antimicrob. Agents Chemother. 50(2), 819-821 (2006).
44. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds. Antimicrob. Agents Chemother. 52(2), 761-766 (2008).
45. Brown SD, Traczewski MM. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control. J. Antimicrob. Chemother. 55 (6), 944-949 (2005).
46. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48(8), 3086-3092 (2004).
47. Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem. J. Antibiot. (Tokyo) 59(4), 220-228 (2006).
48. Huynh HK, Biedenbach DJ, Jones RN. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside. Diagn. Microbiol. Infect. Dis. 55(3), 241-243 (2006).
49. Ueda Y, Kanazawa K, Eguchi K, Takemoto K, Eriguchi Y, Sunagawa M. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem. Antimicrob. Agents Chemother. 49(10), 4185-4196 (2005).
50. Bouchillon S, Hackel M, Johnson J, Poupard J, Pace J. The carbapenem PZ-601 (SMP-601) has potent in vitro Gram-positive, Gram-negative and anaerobic bacterial activity. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
51. Lolans K, Quinn JP. PZ-601 (SMP-601) susceptibility against Gram-negative pathogens with known resistance mechanisms. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
52. Paterson DL, Adams J, Doi Y. In vitro activity of PZ-601 (SMP-601), a novel carbapenem, against extended spectrum β-lactmase producing organisms. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
53. Fujimoto K, Kanazawa K, Pace J, Xerri L. In vitro activity of SMP-601 (PZ-601) in combination with other antimicrobial agents against SMP-intermediate/resistant Acinetobacter baumannii. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
54. Young C, Rusca A, DiStefano A, Radicioni M, Binelli D, Xerri L. Safety and single dose pharmocokinetics of PZ-601: a novel investigational broad spectrum carbapenem. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
55. Kihara R, Yanagihara K, Morinaga Y et al. Potency of SMP-601, a novel carbapenem, in hematogenous murine bronchopneumonia caused by methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 52(6), 2163-2168 (2008).
56. Kurazono M, Ida T, Yamada K et al. In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 48(8), 2831-2837 (2004).
57. Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Antimicrob. Agents Chemother. (2008).
58. Nagura J, Kijima K, Kurazono M et al. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(8), 3526-3528 (2005).
59. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy. Expert Opin. Investig. Drugs 16(4), 419-429 (2007).
60. Wang SS. J&J antibiotic hits roadblock. Wall St J. D8 (2008).
61. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin. Infect. Dis. 46(5), 647-655 (2008).
62. Widmer AF. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(5), 656-658 (2008).
63. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49(10), 4210-4219 (2005).
64. Denis O, Deplano A, Nonhoff C et al. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals. Antimicrob. Agents Chemother. 50(8), 2680-2685 (2006).
65. Rouse MS, Steckelberg JM, Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn. Microbiol. Infect. Dis. 58(3), 363-365 (2007).
66. Yun HC, Ellis MW, Jorgensen JH. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees. Diagn. Microbiol. Infect. Dis. 59(4), 463-466. (2007).
67. Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. 50(11), 3959-3962 (2006).
68. von Eiff C, Friedrich AW, Becker K, Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob. Agents Chemother. 49(10), 4372-4374 (2005).
69. Srinivasan V, McGowan JEJ, McAllister S, Tenover FC. In vitro activity of ceftobiprole against coagulase-negative staphylococci isolated in the USA. Int. J. Antimicrob. Agents (2008).
70. Lemaire S, Van Bambeke F, Glupczynski Y, Tulkens PM. Intraphagocytic activities of ceftobiprole vs. conventional cephalosporins against methicillin-sensitive (MSSA) and methicillin-resistant S. aureus (MRSA). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
71. Banerjee R, Chambers HF. In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
72. Goldstein F, Perutka J, Cuirolo A et al. Identification and phenotypic characterization of a β-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. Antimicrob. Agents Chemother. 51(7), 2514-2522 (2007).
73. Pillar CM, Aranza MK, Shah D, Sahm DF. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent Gram-positive and Gram-negative isolates of European origin. J. Antimicrob. Chemother. (2008).
74. Thamlikitkul V, Trakulsomboon S. In vitro activity of ceftobiprole against Burkholderia pseudomallei. J. Antimicrob. Chemother. 61(2), 460-461. (2008).
75. Shang W, Queenan AM, Davies TA, Morrow B, Flamm RK, Bush K. Defining ceftobiprole wild-type and resistant populations in Pseudomonas aeruginosa. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, II, USA, 16 September 2007.
76. Kresken M, Brauers J, Korber-Irrgang B, Menke A, Romfeld C. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudamonas aeruginosa by time kill methodology. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
77. Queenan AM, Bush K. More rapid penetrability of ceftobiprole and cefepime compared to ceftazidime into Escherichia coli and Enterobacter cloacae. Presented at: 47 th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
78. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by Gram-positive bacteria. Antimicrob. Agents Chemother. 52(1), 37-44 (2008).
79. Vaudaux P, Gjinovci A, Bento M, Li D, Schrenzel J, Lew DP. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49(9), 3789-3793 (2005).
80. Chambers HF. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 49(3), 884-888 (2005).
81. Kosowska K, Hoellman DB, Clark C et al. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49(5), 1932-1942 (2005).
82. Bogdanovich T, Clark C, Ednie LM et al. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50(6), 2050-2057 (2006).
83. Arias CA, Singh KV, Panesso D, Murray BE. Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including β-lactamase-producing and vancomycin-resistant isolates. Antimicrob. Agents Chemother. 51(6), 2043-2047 (2007).
84. Arias CA, Singh KV, Panesso D, Murray BE. Evaluation of ceftobiprole medocaril against Enterococcus faecalis in a mouse peritonitis model. J. Antimicrob. Chemother. 60(3), 594-598. (2007).
85. Ednie LM, Shapiro S, Appelbaum PC. Amtianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn. Microbiol. Infect. Dis. 58(1), 133-136. (2007).
86. Queenan AM, Shang W, Kania M, Page MG, Bush K. Interactions of ceftobiprole with β-lactamases from molecular classes A to D. Antimicrob. Agents Chemother. 51(9), 3089-3095. (2007).
87. Iizawa Y, Nagai J, Ishikawa T et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother. 10(3), 146-156 (2004).
88. Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob. Agents Chemother. 49(8), 3501-3512 (2005).
89. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60(2), 300-311 (2007).
90. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin PPI-0903 active against methicillin resistant Staphylococcus aureus in routine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob. Agents Chemother. 50(4), 1376-1383 (2006).
91. Jacqueline C, Caillon J, Le Mabecque V et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51(9), 3397-3400 (2007).
92. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 5100), 3612-3616 (2007).
93. Mushtaq S, Warner M, Miossec C, Woodford N, Livermore DM. NXL 104/ cephalosporin combinations vs Enterobacteriaceae with CTX-M ESBLs. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
94. Miossec C, Poirel L, Livermore DM et al. In vitro activity of the new β-lactamase inhibitor NXL 104: restoration of ceftazidime efficacy against carbapenem-resistant Enterobacteriaciae stains. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
95. Stachyra T, Pechereau MC, Petrella S et al. Activity of the new β-lactamase inhibitor NXL 104 against KPC β-lactamases. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
96. Cottagnoud P, Merdjan H, Acosta F et al. pharmacokinetics of die new β-lactamase inhibitor NXL 104 in an experimental rabbit meningitis model: restoration of the bacteriological efficacy of ceftazidime against a class C producing K. pneumoniae. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
97. Merdjan H, Tarral A, Girard AM et al. Safety, single dose pharmacokinetics and pharmacodynamics of β-lactamase inhibitor NXL 104 in healthy young male adults. Presented at: 47th Intericience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
98. Buynak JD. The discovery and development of modified penicillin- and cephalosporin-derived β-lactamase inhibitors. Curr. Med. Chem. 11(14), 1951-1964 (2004).
99. Buynak JD, Kalp M, Bethel CR, Carey MP, Bonomo RA. SA-1-204, a novel 6 alkylidene penam sulfone β-lactamase inhibitor, is effective again Escherichia coli, expressing SHV β-lactamases. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
100. Padayatti PS, Sheri A, Totir MA et al. Rational design of a β-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penain sulfone. J. Am. Chem. Soc. 128(40), 13235-13242 (2006).
101. Petersen PJ, Jones CH, Bradfbrd PA. In vitro activity of piperacillin in combination with the penem β-lactamase inhibitor bli-489 against a predictor panel of characterized β-lactamase producing organisms. Presented at: 47th Intencience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
102. Petersen PJ, Jones CH, Bradford PA. In vivo efficacy of the penem β-lactamase inhibitor BLI-489 in combination with piperacillin in murine infection models. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
103. Bowker KE, Noel AR, Macgowan AP. In vitro potency of BAL 30376 against Gram-negative bacilli (GNR). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
104. Bowker KE, Noel AR, Macgowan AP. A monobactam plus double β-lactamase inhibitor combination (BAL 30376) designed to overcome multiple resistance in Gram-negative bacilli: proof of concept in an in vitro pharmacokinetic model. Presented at: 47th Interscience Conference on Antimicrobial Agent and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
105. Desarbre E, De Fontage A, Page MGP, Richalet F, Roussel P. Antimicrobial activity of novel monobactams. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
106. Hujer AM, Desarbre E, Endimiani A, Paterson DL, Page MGP, Bonomo RA. Activity of BAL 30376 agains MDR Klebsiella and Acinetobacter spp.. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
107. Page MGP, Desarbre F, Geier C, Hofer B. Activity of monobactam β-lactamase inhibitor combinations against β-lactam resistant Gram-negative bacteria. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
108. Long DD, Aggen J, Chinn J et al. A multivalent approach to drug discovery for novel antibiotics: TD-1792. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
109. Then RL. β-lactam quinolone hybrids. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics. Chicago, IL, USA, 16 September 2007.
110. Jones RN, Barry AL, Thornsberry C. Antimicrobial activity of RO 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime. Antimicrob. Agents Chemother. 33(6), 944-950 (1989).
111. Georgopapadakou NH, McCaffrey C. β-lactamase hydrolysis of cephalosporin 3′-quinolone esters, carbamates, and tertiary amines. Antimicrob. Agents Chemother. 38(5), 959-962 (1994).
112. Peters NK, Dixon DM, Holland SM, Fauci AS. The research agenda of the national institute of allergy and infectious diseases for antimicrobial resistance. J. Infect. Dis. 197(8), 1087-1093 (2008).
113. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 197(8), 1079-1081 (2008).